Clinical Trial Update: Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk [Phase 3]

View source ↗

Summary

Phase 3 trial comparing rivaroxaban to aspirin in high-risk type 2 diabetes patients with subclinical inflammation; results completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Aspirin (Aspirin)
• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: GWT-TUD GmbH | Conditions: Type 2 Diabetic Patients | Phase 3 | Status: COMPLETED | Results posted: 2023-11-07